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Although several cytokines and their receptors have
been involved in the development of psoriasis, the etiol-
ogy is still unknown. In this study we looked for genes
possibly involved in the disease by the reverse transcrip-
tion^polymerase chain reaction di¡erential display
technique in lesional and nonlesional skin biopsies from
psoriatic patients.We found the mRNA of the a1 chain
of the interleukin-13 receptor expressed di¡erentially in
psoriatic biopsies. By reverse transcription^polymerase
chain reaction, we con¢rmed an overexpression of the
a1 chain of the IL-13 receptor and a chain of the inter-
leukin-4 receptor mRNA in lesional skin psoriatic
biopsies, when compared with skin biopsies from
healthy subjects (po0.01).The nonlesional skin obtained
from a region close to a lesional zone in psoriatic pa-
tients presented also an overexpression of these mRNA
in 50% of the samples. Interleukin-13 and interleukin-4
were not detected either as mRNA or as the proteins in
any of the biopsies from psoriatic patients or healthy
subjects. A monoclonal antibody to the a1 chain of the
interleukin-13 receptor detected the receptor in the epi-
dermal keratinocytes of psoriatic patients and of
healthy subjects; however, the positive antibody reac-
tion was stronger in skin tissue from healthy subjects
than in psoriatic lesional skin tissue (po0.01), although
the mRNA was overexpressed. As interleukin-13 is a
pleiotropic immunoregulatory cytokine with a variety
of e¡ects on di¡erent cell types, including monocytes,
B lymphocytes, mast cells, and keratinocytes, we sug-
gest, based on our results, that the interleukin-13 recep-
tor possibly plays an important part in the early
in£ammatory process of psoriasis; however, its function
is lost in the psoriatic keratinocytes. Key words: Inter-
leukin-13/receptor psoriasis/kerationocytes/IL-13 J Invest
Dermatol 119:1114 ^1120, 2002
P
soriasis is a chronic skin disease characterized by a hy-
perproliferation of keratinocytes and by an immuno-
logic cellular in¢ltrate, including activated T lympho-
cytes, producing multiple cytokines that can in£uence
the epidermal keratinocytes. The speci¢c mechanism
through which the keratinocytes attain their hyperproliferative
state in psoriasis is unknown. The proliferation and the di¡eren-
tiation of keratinocytes is controlled by growth factors and cyto-
kines, such as the epidermal growth factor, keratinocyte growth
factor, transforming growth factor-a, granulocyte-macrophage
colony-stimulating factor, interleukin (IL)-1, IL-6, IL-8, and
tumor necrosis factor-a (Kupper et al, 1986; O’Keefe et al, 1988;
Kamalati et al, 1989; Brown and Halper, 1990; Kock et al, 1990;
Luger and Schwarz, 1990) some of which are produced by the kera-
tinocytes themselves. The expression of some of these cytokines
is upregulated in in£ammatory skin diseases, and these cytokines
are mediators of the leukocyte chemotaxis and the in£ammatory
and immune responses (Nickolo¡, 1991; Nickolo¡, 1999).
At the molecular level, the overexpression of growth factors
and pro-in£ammatory cytokines and their receptors has been de-
scribed in psoriatic patients. The IL-12 produced by antigen-pre-
senting cells very early during infection in vivo has an important
pro-in£ammatory function. This cytokine plays a part in the dif-
ferentiation of naive T cells into interferon (IFN)-g-producing T
helper 1 cells (Trinchieri, 1998). IL-12 has already been found
overexpressed in free nerve endings of the epidermis, dermal
nerve ¢bers, and in lesional psoriatic skin (Turka et al, 1995;
Yawalkar et al, 1998). Schon et al (1997) presented evidence that a
particular splenic T cell subset (CD4þCD45Rbhigh) the same T
cell subset that induces colitis in scid/scid mice, induces psoriasis-
like lesions when transferred into minor haplotype mismatched
scid/scid mice. Hong et al (1999); reported that the IL-12, indepen-
dently of IFN-g, plays a crucial part in the pathogenesis of the
murine psoriasis-like skin disorder. On the other hand, IL-17 is
produced by activated CD4þ T cells and can stimulate epithelial
cells. IL-17 together with IFN-g enhances the mRNA and pro-
tein production of pro-in£ammatory cytokines IL-6 and IL-8 as
well as IL-15. It also enhanced the production of intercellular ad-
hesion molecule-1 and HLA-DR in normal human keratino-
cytes. The majority of the CD4þ and CD8þ T cell clones
derived from lesional psoriatic skin expressed IL-17 mRNA, sug-
gesting that skin-in¢ltrating T cells can produce this cytokine. In
addition, IL-17 mRNA is detectable in biopsies from lesional
psoriatic skin, but not in nonlesional control biopsies (Teunissen
et al, 1998). Epidermal keratinocytes from psoriatic skin lesions
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have shown an increase of the expression of pro-in£ammatory
IL-8 and its receptor (IL-8R) (Schulz et al, 1993; Lamster et al,
1995). It has also been demonstrated that the combination of IL-
8 and IFN-g induces the expression of inducible nitric oxide-spe-
ci¢c mRNA and of the functional protein in cultured human
keratinocytes (Kolb-Bachofen et al, 1994). These results suggest
an important role for inducible nitric oxide in conjunction with
IL-8 and its receptor during the early formation of psoriatic le-
sions (Bruch-Gerharz et al, 1996). IL-15 and its receptor inhibit
apoptosis of keratinocytes and have been found to be overex-
pressed in lesional psoriatic epidermis (Rˇckert et al, 2000), possi-
bly contributing in the formation of the psoriatic lesion.
Recently, Blumberg et al (2001) reported that overexpression of
IL-20 in transgenic mice provokes neonatal lethality, with skin
abnormalities, including aberrant epidermal di¡erentiation. His-
tologic analysis of the skin of the IL-20 transgenic mice showed
characteristics similar to that observed in human psoriatic skin;
however, immune in¢ltrates were not observed in the IL-20
transgenic mouse skin. In the biopsies of psoriatic patients there
was overexpression of IL-20Ra and IL-20Rb.
Two other cytokines that are gaining increased importance as
negative modulators of in£ammatory processes are IL-10 and IL-
11. Expression of IL-10 and its receptor have been shown to be
decreased in psoriatic skin. These molecules are down-modulated
by the pro-in£ammatory cytokine IL-8, and are induced by anti-
psoriatic glucocorticosteroids in normal cultured keratinocytes
(Gˇnter et al, 1997). Treatment of psoriatic patients with recombi-
nant human IL-11 caused a reduction in lesion severity that cor-
related with a polarization toward a T helper 2 phenotype in
lesional tissue, as measured by a reduction in IFN-g mRNA and
an elevation of IL-4 mRNA, compared with the pretreatment
levels (Trepicchio et al, 1999). In a cell culture model of murine T
cell di¡erentiation, recombinant human IL-11 acts by inhibiting
IL-12-induced IFN-g production and enhances IL-10 production.
The expression of the IL-11Ra and the cytokine were detected in
human and murine CD4þ and CD8þ lymphocytes, which sug-
gests that recombinant human IL-11 can directly interact with T
cells (Bozza et al, 2001).
In order to ¢nd other molecules that could be involved in
psoriasis, in this study we used the reverse transcription^poly-
merase chain reaction^(reverse transcription^PCR) di¡erential
display technology, in lesional and nonlesional skin from psoria-
tic patients. We found overexpression of IL-13 receptor a1
(IL-13Ra1) mRNA in lesional skin, but a low expression of the
protein.
MATERIALS AND METHODS
Human skin samples For the reverse transcription^PCR di¡erential
display assay 4 mm skin biopsies were taken from lesional and non-
lesional skin from three patients with untreated psoriasis. For the gene
expression analysis (reverse transcription^PCR) and the immuno-
histochemical studies, biopsies from lesional and nonlesional skin were
taken from another 10 patients with psoriasis. Biopsies of lesional skin
were taken from one patient each with atopic dermatitis, polymorphous
light eruption, pemphigus vulgaris, lichen planus, seborrheic keratoses,
and dermato¢broma. Biopsies of normal skin were also taken from 10
healthy subjects, which were used as a control group. Every fresh biopsy
was cut into two parts. One part was immediately frozen in liquid
nitrogen and was used for RNA extraction and the other part was ¢xed
in 4% p-formaldehyde and used for immunohistochemical analysis.
Written consent was obtained from each patient and healthy controls
according to the ethics protocol registered at the Hospital General de
MeŁ xico.
Di¡erentiated primary keratinocyte cultures and IL-13
treatment Normal human keratinocytes were prepared from neonatal
foreskins according to Keratinocyte-Serum Free Medium (K-SFM)
instructions (Gibco-BRL, Life Technologies, Rockville, MD). The cells
were grown until 65% of con£uence in a humidi¢ed atmosphere with
5% CO2 at 371C in K-SFM supplemented with 20 mg per ml bovine
pituitary extract and 0.1 ng per ml epidermal growth factor (Gibco-BRL,
Life Technologies). Subcultures were done in p60 mm petri dishes and the
di¡erentiation of cells was induced by incubation in supplemented K-SFM
containing 10% fetal bovine serum. On day 3 fresh medium was added to
each dish. After 5 d, the di¡erentiated keratinocytes were treated with IL-
13 (25 ng per ml) in fresh supplemented K-SFM with fetal bovine serum
during 18 h. The total RNAwas obtained withTrizol reagent (Gibco BRL
Life Technologies).
RNA isolation To minimize RNA degradation, frozen skin biopsies
were homogenized in Trizol reagent (Gibco BRL) with a tissue homo-
genizer (Pro Scienti¢c, Inc. Oxford, CT). RNA was obtained by the
Trizol reagent method. Contaminating DNAwas removed by treating the
RNA with deoxyribonuclease I (Gibco BRL, Life Technologies). The
RNA pellet was dissolved in RNase-free water and the amount of RNA
was determined by spectrophotometry at 260 nm. The integrity of RNA
was analyzed in a 0.8% agarose gel electrophoresis.
Reverse transcription^PCR di¡erential display The reverse
transcription^PCR di¡erential display technique was performed by the
method of Liang and Pardee (1992). cDNAwere then synthesized in 20 ml
RNase-free reaction containing 3 mg of deoxyribonuclease-treated total
RNA, 500 mM deoxynucleoside triphosphates (Pharmacia, Piscataway, NJ),
10 mM dithiothreitol (Gibco BRL, Life Technologies), 1 U of RNase
inhibitor (Promega, Madison, WI), 2.5 mM of one of three oligo dT11M
degenerate primers (where M¼G, A, or C), 1¢rst-strand bu¡er and
200 U of SuperScript II RNase H^ Reverse Transcriptase (Gibco BRL,
Life Technologies). The reactions were incubated for 1 h at 421C. The
cDNA was ampli¢ed by PCR in a 25 ml reaction containing the same
dT11M primer (2.5 mM), 0.5 mM of one of 20 arbitrary 10 mer primer
(decamer) of random sequence (AP1-20; Gen Hunter, Nashville,TN), 1 ml
of the cDNA reaction (diluted 1 : 10), 1PCR bu¡er, and additional 2 mM
MgCl2 and 1 U ofTaq DNA polymerase (Gibco BRL, Life Technologies).
The reaction was incubated in aTechne thermocycler (Cambridge) at 921C
for 3 min followed by 45 cycles at 921C for 40 s; at 421C for 1min; at 721C
for 1 min. Finally, it was kept at 721C for 5 min and then held at 41C.
Ampli¢ed fragments were separated in a 6% polyacrylamide gel
(Cleangel DNA Analysis Kit; Pharmacia) for 4 h. Gels were stained with
a silver stain kit (Bio-Rad, Hercules, CA). The di¡erential bands were
excised from the gel, heated in 100 ml of water for 10 min, cooled to room
temperature, and brie£y spun in a microfuge (ICE, Micromax RF,
Needham Heights, MA). The supernatant was transferred to a fresh
microfuge tube and the fragment precipitated in the presence of 10 mM
glycogen, 0.3 M sodium acetate, and 2 volumes of ethanol (EtOH)
at ^201C for 30 min The DNA pellet was washed with 70% EtOH,
dried, and resuspended in 10 ml of sterile water. The excised bands were
re-ampli¢ed in a 40 ml reaction with the same set of primers used to
generate it. Reactions containing the correct size band were cloned into
the pCRII vector as recommended by the supplier (Invitrogen, San
Diego, CA). Recombinant plasmids were run through electrophoresis in a
1% agarose gel and puri¢ed with the Qiagen kit (Qiagen, Chatsworth,
CA) for DNA sequencing.
DNA sequencing PCR fragments cloned into the pCRII vector were
sequenced via the BigDyet terminator Cycle Sequencing kit (Applied
Biosystems, Foster City, CA). The sequences were compared with those
stored in the DNA sequence database via the BLASTN and FASTA
programs of the NIH server (Altschul et al, 1990).
Northern analysis Fifteen micrograms of total RNA of lesional and
nonlesional skin biopsies from a psoriatic patient were run through
electrophoresis in 1% agarose-formaldehyde-gels as performed byThomas
(1980). The gel was soaked in 20 SSPE bu¡er (3M NaCl, 0.2 MNaH2
PO4-H2O, 25 mMEDTA; pH7.4 for 1 h, blotted on to a Hybond-N
þ
nylon membrane (Amersham Pharmacia Biotech, Piscataway, NJ) and
hybridized with 32P-labeled cDNA probes at 551C overnight. The
membranes were washed at 621C in 0.1sodium citrate/chloride bu¡er
and 1% sodium dodecyl sulfate for 15 min and autoradiographed on
Kodak ¢lm.
Reverse transcription^PCR analysis First strand cDNAwas prepared
from 3 mg of RNA and 0.5 mg of oligo (dT)12^18 primers using Moloney
Murine Leukemia Virus Reverse Transcriptase (Gibco BRL, Life
Technology) under the conditions suggested by the supplier. After the
reverse transcription, ampli¢cation was carried out by PCR using Taq
DNA polymerase (Gibco BRL, Life Technology) with 1 mM MgCl2 in a
Techne thermocycler (Cambridge). PCR was performed with the
following primers: for IL-13Ra1 (50 -CACAGTGTCCAAATAATGGTC-
AAGG-30 and 50 -TCAAAGTATCAGGAAGAACACCAGG-30), yielding
a 320 bp product; for IL-13Ra2 (50 -GGGACCTATTCCAGCAAGGT-
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G-30 and 50 -TGAGACTCATATTGAACATTTGGCC-30), yielding a 433 bp
product; for IL-4Ra (50 -GTCTGCAGATGAGGACTAGGGC-30 and 50 -
TACTCTCATGGGATGTGGCG-30) yielding a 200 bp product; for
IL-13 (50 -TGGAGCATCAACCTGACAGC-30 and 50 -TCCTTTACAAA-
CTGGGCCACC-30) yielding a 189 bp product; for IL-4 (50 -CCGAGTT-
GACCGTAACAGACATC-30 and 50 -TGGTTGGCTTTTCACAGG-30)
yielding a 241 bp product; for b-actin (50 -GTGGGGCGCCCCAGGC-
ACCA-30 and 50 -CTCCTTAATGTCACGCACGATTTC-30) yielding a
550 bp product. Cycle times were 40 s at 921C, 50 s at 551C, and 30 s at
721C for 30 cycles. Products were separated on agarose gels and stained
with ethidium bromide. A mock PCR (without cDNA) was included to
exclude contamination in all experiments. To evaluate mRNA expression
semiquantitatively, b-actin message expression was used to normalize the
cDNA amount to be used. The intensity of the ampli¢ed band was
measured in an Imager Ready Apparatus (Alpha Innotech Corporation,
San Leandro, CA) to obtain the IL-13R or IL-4R/b-actin relation.
Immunohistochemical analysis The immunohistochemical analysis
was developed in 7 mM p-formalized-para⁄n sections of biopsies. Mouse
monoclonal antibody (MoAb) to human IL-13Ra1 (Diaclone, BesancU on,
Bourgogne, France), rabbit polyclonal IgG to IL-4Ra (Santa Cruz
Biotechnology), mouse MoAb to human IL-13 (Pharmingen, San Diego,
CA) and to human IL-4 (Pharmingen) were used to assess expression of
the proteins, followed by secondary biotinylated anti-mouse or anti-
rabbit, ampli¢ed with immunoperoxidase (DAKO EnVisiont System
Peroxidase, Carpinteria, CA), and visualized with diaminobenzidine as
chromogen. For negative controls, the ¢rst MoAb was either omitted or
replaced by an irrelevant isotype-matched reagent. Staining intensity was
scored with a digital Imager ReadyApparatus (Alpha Innotech Corporation).
RESULTS
Di¡erential expression of mRNA of IL-13Ra1 in lesional
skin from patients with psoriasis Our criterion for
di¡erentially regulated PCR fragments was to select those bands
present in at least two of the three psoriatic biopsies and absent
from any control samples (or vice-versa). We found this to be
the best way to prevent isolation of false positives due to natural
genetic variability among people and/or endogenous PCR
variability. When we developed a reverse transcription^PCR
di¡erential display reaction with T11G and AP4 primer, we
observed a 580 bp band of cDNA that was expressed in lesional
skin but not in the nonlesional skin of the three psoriasis patients
studied (Fig 1A). This re-ampli¢ed and 32P-labeled band only
hybridized with the RNA of lesional skin and not with the
RNA of nonlesional skin of a psoriatic patient (Fig 1B). The
probe for b-actin used as control hybridized with identical
intensity with both RNA (Fig 1C). When the band of 580 bp
was cloned and the nucleotide sequence determined, we found
that this sequence corresponds to the mRNA of IL-13Ra1.
Reverse transcription^PCR expression of IL-13Ra1 mRNA
and IL-4R mRNA in skin biopsies from psoriatic patients
and control subjects IL-13Ra1 expression was analyzed by
reverse transcription^PCR in 10 lesional and nonlesional
biopsies of psoriatic patients. We observed that IL-13Ra1
mRNA was overexpressed (320 bp band) in a 100% of the
lesional skin from psoriatic patients (Fig 2A) as compared with
the lower expression in the skin of healthy subjects (Fig 2B), of
which only one subject (10%) overexpressed this molecule but to
a lesser degree. Five of the 10 patients (50%) also overexpressed
the IL-13Ra1 mRNA in the nonlesional skin (Fig 2A, lanes 6^10),
which was taken from a healthy region, about 1 cm from a
psoriatic plaque. In the biopsies from patients with other
dermatologic diseases (Fig 2A, lanes 11^16) and in the
nondi¡erentiated and di¡erentiated keratinocytes obtained from
primary culture of keratinocytes (Fig 2B, lanes 13 and 14), the
expression of the IL-13Ra1 mRNA was low, similar to that
from the skin of the 10 healthy subjects studied. The di¡erenti-
ated keratinocytes stimulated with IL-13 did not overexpress the
IL-13Ra1mRNA (Fig 2B, lane 15) but did express the IL-13Ra2
mRNA (Fig 2B, lane 17). A lesional and nonlesional skin biopsy
from one patient did not express the IL-13Ra2 mRNA (data not
shown). When we semiquanti¢ed the intensity of the RNA
expression and determined the IL-13Ra1/b-actin ratio, we found
a signi¢cant di¡erence in the mean intensity of expression of the
IL-13Ra1 mRNA between the psoriatic lesional skin and the
skin from healthy subjects (po0.01). Even though 50% of
nonlesional skin of the patients with psoriasis overexpressed the
mRNA of IL-13R there was a signi¢cant di¡erence between
lesional skin and nonlesional skin of the psoriatic patients
(po0.05, and between the nonlesional psoriatic skin and the
skin of healthy subjects (po0.05) (Fig 3A).
As human IL-13 and IL-4 share the same receptor, we studied
the expression of IL-4Ra in the samples and found also a
di¡erential overexpression of IL-4Ra (200 bp band) similar
to that observed for the IL-13Ra1 in the psoriatic patients
(Fig 2C). The 10 skin biopsies from healthy subjects also
expressed the molecule but with lower intensity than the
lesional skin of patients with psoriasis (Fig 2D). When we
determined the relation IL-4R/b-actin we only found a
signi¢cant di¡erential expression between the lesional skin from
patients with psoriasis and the skin from healthy subjects
(po0.01) and between the lesional and nonlesional skin of the
patients with psoriasis (po0.05). (Fig 3B).
Figure1. Di¡erential expression of IL-13Ra1 mRNA in lesional and nonlesional skin from patients with psoriasis. Panel A: 6% PAGE stained
with silver, of reverse transcription^PCR di¡erential display analysis of nonlesional (NL) and lesional (L) skin from three patients with psoriasis. Reverse
transcription^PCR di¡erential display was developed withT11G and Ap4 primers. The arrows indicate the di¡erential band which corresponded to mRNA
to IL-13Ra1. Lane M contains a DNA size marker. Panels B and C: northern blot analysis with total RNA of nonlesional (NL) and lesional (L) skin from
one patient with psoriasis. The cDNA of 580 bp obtained from the reverse transcription^PCR di¡erential display was used as probe (32P-labeled) to detect
the IL-13Ra1 mRNA (panel B). The paper was washed and incubated another one with 32P-labeled probe to b-actin, which was obtained by reverse tran-
scription^PCR.
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Reverse transcription^PCR expression of IL-13 mRNA and
IL-4 mRNA in skin biopsies from psoriatic patients and
control subjects When we studied the expression of the
cytokines IL-13 (189 bp band) and IL-4 (241 bp band) in the
skins of patients and healthy subjects, we did not ¢nd expression
of the two cytokines in any of the studied samples. We used
phytohemagglutinin-activated mononuclear cells obtained from
bronchial lavage of a patient with asthma as positive expression
of IL-13 and IL-4 (data no shown).
Immunohistochemical detection of IL-13Ra1, IL-4Ra,
IL-13, and IL-4 in the biopsies of the patients with
psoriasis The histopathologic analysis of the lesional skin
biopsies was characteristic of a psoriatic skin, with an intense
leukocyte in¢ltrate, whereas all the nonlesional biopsies were
identical to the biopsies of healthy subjects.
To analyze the distribution of IL-13Ra1, immunohistologic
staining was performed on skin sections derived from lesional
and nonlesional skin of psoriasis patients, as well as skin sections
from normal healthy donors. Staining of lesional psoriatic tissues
with the MoAb IL-13Ra1, revealed the expression of the protein
in the epidermal keratinocytes (Fig 4C,F). Also, positive results
were observed, in nonlesional skin of psoriatic patients and in
the skin of healthy subjects (Fig 4B,E and A,D, respectively). In
most samples, however, the intensity of the positive reaction was
higher in the skin of healthy subjects and in nonlesional skin
than in lesional skin from psoriatic patients.We observed that as
the psoriatic lesion increases in size, the intensity of the reaction
decreases. The mean score of intensity in healthy skin was
approximately twice as high as that in psoriatic skin (52.93 in
healthy skin vs 28.02 in psoriatic skin, po0.01). The mean score
of nonlesional skin was 41.67 (po0.05 lesional vs nonlesional
skin and p40.05, nonlesional vs healthy skin).
When we analyzed by immunohistochemistry the expression
of IL-4Ra, we observed a positive staining in the epidermal
keratinocytes, with a similar score of intensity in all three types
of tissue assayed (p40.05) (Fig 4J^L). Hodgkin lymphoma tissue
sections were used as a positive control for IL-13Ra1 and IL-4Ra
(data not shown).
To corroborate the expression of the IL-13Ra1 in keratinocytes
we used nondi¡erentiated and di¡erentiated keratinocytes
from the primary culture and we observed that these cells
were also stained with the MoAb IL-13Ra1 (Fig 4G and
4H, respectively).
Staining of the healthy skin and psoriatic tissues with the
MoAb to IL-13 and IL-4 was negative. Mononuclear peripheral
blood cells from an asthma patient were used as a positive
control for these cytokines (data not shown).
DISCUSSION
In an e¡ort to identify and clone psoriasis-speci¢c genes, Rivas
et al (1997) using the reverse transcription^PCR di¡erential
Figure 2. Reverse transcription^PCR expression analysis of IL-13Ra1 mRNA and of IL-4Ra mRNA in skin samples of patients and con-
trols. Panel A: reverse transcription^PCR for IL-13Ra1 in nonlesional (NL) and lesional (L) skin biopsies from 10 patients with psoriasis (lanes 1^10).
Reverse transcription^PCR of IL-13Ra1 in lesional skin biopsies from patients with other dermatologic diseases such as: atopic dermatitis (lane 11), poly-
morphous light eruption (lane 12), pemphigus vulgaris (lane 13), seborrheic keratoses (lane 14), lichen planus (lane 15), and dermato¢broma (lane 16).
M¼DNA size marker, C1¼Cos-7 cells (used as positive control of expression of IL-13Ra1 and IL-4Ra). Panel B: reverse transcription^PCR of IL-
13Ra1 in skin biopsies from 10 healthy subjects (lanes 1^10). Reverse transcription^PCR of IL-13Ra1 in nonlesional (lane 11) and lesional (lane 12) skin
biopsies from psoriatic patient 1. Reverse transcription^PCR of IL-13Ra1 in nondi¡erentiated (lane 13), di¡erentiated keratinocytes (lane 14), di¡erentiated
keratinocytes treated with IL-13 (lane 15). Reverse transcription^PCRof IL-13Ra2 in di¡erentiated keratinocytes nontreated (lane 16) and treated with IL-13
(lane 17). Panel C: reverse transcription^PCR of IL-4Ra in nonlesional (NL) and lesional (L) skin biopsies from 10 patients with psoriasis (lanes 1^10).
C1¼Cos-7 cells. Panel D: reverse transcription^PCRof IL-4Ra in skin biopsies from 10 healthy subjects (lanes 1^10). Lane M contains a DNA size marker.
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display technique in biopsies from psoriatic patients, found a
di¡erential expression of four genes not previously described in
psoriasis: connexin 26 (gap junction protein), squamous cell car-
cinoma antigen-1 (a serine protease inhibitor), and mitochondrial
NAD subunits 5 and 6. Later, Di Sepio et al (1998) used the same
technique in keratinocyte lines treated in vitro with tazarotene,
and identi¢ed a tumor suppressor gene (TIG-3), which was found
later in biopsies from psoriatic patients treated with tazarotene.
In this study, with the same technique we detected a di¡eren-
tial expression of mRNA of the IL-13Ra1 in three biopsies from
psoriatic patients. Afterwards we con¢rmed this di¡erential over-
expression between the lesional skin of 10 more psoriasis patients
and the skin of 10 healthy subjects (po0.01). It is important to
point out that the mRNA for IL-13Ra1 was also overexpressed
in 50% of the nonlesional skin of the patients studied, which can
be explained because biopsies were taken from an area very near
to the lesional tissue and, although they were histologically
healthy, the results indicate di¡erences at the molecular level.
The overexpression of IL-13Ra1 was speci¢c of psoriasis. The
control patients with atopic dermatitis and polymorphous light
eruption, which are mediated by T helper 2 lymphocytes, pre-
sented lower expression of this receptor, as did the control pa-
tients with other dermatologic diseases.
As the IL-13R complex is composed of two di¡erent chains,
IL-13Ra1 or IL-13Ra2, and IL-4Ra (Hilton et al, 1996), we
looked for the expression of the IL-4Ra mRNA in the skin of
patients with psoriasis and we found a similar di¡erential overex-
pression between the lesional skin from psoriatic patients and
skin from healthy subjects (po0.01), which con¢rms the overex-
pression of the IL-13R complex. Our results are as those reported
by Prens et al (1996) by in situ hybridization; they detected an in-
creased expression of IL-4R mRNA in the psoriatic cells, but
they did not study the expression of IL-13Ra1 mRNA.
Four structural models of IL-13R involving di¡erent combi-
nations of IL-13Ra1, IL-13Ra2, or IL-4Ra have been proposed
(Murata et al, 1997). IL-13Ra1 binds IL-13 with low a⁄nity by
itself, but when paired with IL-4Ra, it binds IL-13 with high
a⁄nity and forms a functional IL-13R. IL-13Ra1 chain presents
the tyrosine residues that mediate the activation of signal trans-
duction by means of STAT3 and STAT6. In contrast, IL-13Ra2,
by itself, binds IL-13 with high a⁄nity, but does not cause activa-
tion of its signaling pathway (Osawa et al, 2000; Umeshita-Suya-
ma et al, 2000; Kawakami et al, 2001). We observed that IL-13
induces the expression of IL-13Ra2 mRNA but not of IL-
13Ra1 mRNA in di¡erentiated keratinocytes of a primary cul-
ture. Similar results were obtained by David et al (2001), although
not in primary culture, but in a human keratinocyte cell line (Ha-
CaT) treated with both IL-13 and IL-4; furthermore, they found
that these two cytokines did not induce the overexpression of IL-
4Ra. In a di¡erent model, endothelial cells treated with tumor
necrosis factor-a, Lugli et al (1997) found overexpression of IL-
4Ra but not of IL-13R mRNA. In our study, we detected an
overexpression in the psoriatic lesions of both IL-13Ra1 and IL-
4Ra mRNA, which could be playing an important part in psor-
iasis; however, we do not know what that role could be, nor
which the inducer is. All these results indicate the di¡erences in
modulation of receptor expression, in di¡erent target cells, by
di¡erent inducers.
The immunohistochemical assay with MoAb IL-13Ra1 re-
vealed that the epidermal keratinocytes of the nonlesional and le-
sional biopsies of patients with psoriasis and of skin biopsies from
healthy subjects were expressing the IL-13R. This result corre-
lated with the di¡erentiated and nondi¡erentiated keratinocytes
from primary cultures, used as control, which also expressed this
receptor. Akaiwa et al (2001), demonstrated, by immunohisto-
chemistry, the expression of IL-13R in keratinocytes, hair folli-
cles, and sebaceous and sweat glands of the skin from healthy
subjects; however, we observed that the intensity of the reaction
with the speci¢c MoAb decreases as the histologic severity of
psoriatic lesions increases, and there was no correlation with over-
expression of mRNA. These results suggest that the IL-13R is
normally present in the skin of all subjects, but when the psoria-
tic process is triggered, the mRNA to IL-13Ra1 is overexpressed,
producing its receptor. Then, IL-13 could have an important ef-
fect in the normal keratinocyte, but the expression of the protein
is stopped by an unknown mechanism as the lesion advances.We
observed a similar phenomenon with IL-13RJ as reported for IL-
10 in psoriatic patients, human keratinocytes do not produce IL-
Figure 3. Comparison of the expression of IL-13Ra1 mRNA (panel A) and IL-4Ra mRNA (panel B) in nonlesional (NL) and lesional (L)
skin from psoriatic patients, skin from healthy subjects, and skin from patients with other dermatologic diseases (ODD).The intensity of each
band was measured in the Imager Ready Apparatus (Alpha Innotech Corporation) and normalized against that of b-actin. Bars indicate the mean of in-
tensity.Variance analysis was done by the Duncan method.
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10 under normal conditions (Teunissen et al, 1997) and, although
IL-10 was not detected by immunostaining in psoriatic epidermis
(Nickolo¡ et al, 1994), IL-10 mRNA has been detected in psoriatic
lesions by reverse transcription^PCR (Olaniran et al, 1996).
Furthermore, a functional receptor for IL-10 has been demon-
strated on normal human keratinocytes and its expression is dra-
matically decreased in acute lesional but not in the nonlesional
psoriatic epidermis (Gˇnter et al, 1997).
On the other hand, in contrast to the results obtained with
mouse MoAb to IL-13Ra1, with the rabbit polyclonal IgG anti-
body to IL-4Rawe observed a positive reaction in the epidermal
keratinocytes with similar intensity in the three tissues assayed.
As mentioned above, Prens et al (1996), found by immunohisto-
chemistry the IL-4Ra protein overexpressed in psoriatic lower
epidermal layers.
IL-13 and IL-4 or their mRNAwere not found in any of the
assayed tissues. IL-4 mRNAwas also undetectable in skin homo-
genates of psoriatic lesions by other groups (Uyemura et al, 1993;
Prens et al, 1996). These results suggest that the induction of the
overexpression of mRNA IL-13Ra1 in the psoriatic keratinocytes
is not induced by the IL-13 and IL-4 cytokines. We have con-
¢rmed in a primary culture of keratinocytes the results obtained
by David et al (2001), in a keratinocyte cell line, that the IL-13
does not modulate the overexpression of mRNA IL-13Ra1.
Nevertheless, we cannot discard the possibility that cytokines
produced by other cells could induce the overexpression of the
mRNA of IL-13Ra1 in the psoriatic keratinocyte.
The relevance of the elevated mRNA IL-13R expression ob-
served in psoriatic keratinocytes in this study is not entirely clear,
because the e¡ects of IL-13 in the keratinocytes are seldom stu-
died.
It is known that IL-13 is produced predominantly byT helper 2
lymphocytes, and acting together with IL-4, has e¡ects on several
immune cells, including B lymphocytes and macrophages, stimu-
lating their proliferation, di¡erentiation, and e¡ector functions.
In immune cells, these cytokines inhibit the production of in-
£ammatory cytokines (IL-1, IL-6, IL-8, and tumor necrosis fac-
tor-a) (Minty et al, 1993; DeWaal et al, 1993) and the IL-13 and IL-
4 could down-modulate, together with IL-10 and IL-11 (Gˇnter
et al, 1997; Trepicchio et al, 1999; Bozza et al, 2001), the in£amma-
tory processes of psoriasis.
The overexpression of IL-13R in certain epithelial tumors is
associated with a clear growth-inhibitory response to IL-13 by
those tumor cells (Serve et al, 1996). IL-13 in the psoriatic kerati-
nocytes could be playing a part in the down-modulation of the
in£ammatory and proliferative processes of psoriasis; however,
the e¡ect of IL-13 on the proliferation or in the inhibition of
proliferation of normal and psoriatic keratinocytes has not been
studied.
In contrast, IL-13 and IL-4 synergistically increase RANTES
production by normal keratinocytes treated with IFN-g (Waku-
gawa et al, 2001), and IL-13 stimulated IL-6 production in normal
human keratinocytes (Derocq et al, 1994) and human lung ¢bro-
blast (Doucet et al, 1998). There are reports that the IL-6 produc-
tion is increased in monocytes and keratinocytes from patients
with psoriasis (Neuner et al, 1991). IL-8 is another in£ammatory
cytokine that is modulated by IL-13 in a human colon epithelial
cell line (Kolios et al, 1996). Expression of adhesion molecules is
increased by IL-13 and IL-4 in human endothelial cells (Koto-
wicz et al, 1996) and human lung ¢broblasts (Doucet et al, 1998).
These reports suggested that the IL-13 in keratinocytes of patients
with psoriasis could induce the production of adhesion molecules
and in£ammatory cytokines, which could be markers of the in-
itiation of the in£ammatory process of psoriasis.
On the other hand CDw60 is an acetylated form of the GD3
ganglioside that is expressed in keratinocytes and T lymphocytes
from psoriatic patients (Skov et al, 1997), but also is present in
other tissues from normal subjects (Gocht et al, 2000). T cell
clones from lesional psoriatic skin, activated with anti-CDw60
antibody in the presence of accessory cells and/or phorbol ester,
and the lymphokines released by these T cells, were capable of
inducing intercellular adhesion molecule-1 and HLA-DR expres-
sion on normal keratinocyte cultures (Baadsgaard et al, 1990).
High expression of CDw60 in normal keratinocytes is induced
by IL-13 and IL-4 from activated T cells from psoriatic patients
and this high induction is blocked by IFN-g (Huang et al, 2001).
CDw60 acts as a costimulator for T cell activation, but its role on
the psoriatic keratinocytes is still unknown.
We propose that the altered expression of IL-13R in psoriasis
might play an important part in the initiation and in the devel-
opment of the disease. Much further work is needed to under-
stand fully the involved mechanisms.
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